Skip to main content

Table 1 Ibrutinib in clinical trials for chronic lymphoid leukemia

From: Ibrutinib for B cell malignancies

Studies

Phase Ib/II for CLL/SLL

Phase Ib/II for CLL patients (N=116) [26]

Ibrutinib

Ibrutinib

+

+

     

Rituximab

Ofatumumab

 

(High risk refractory/relapsed)

Treatment naïve patients >65 years old

Relapsed/refractory

High risk relapsed/refractory

(Relapsed/refractory CLL)

(Relapsed/refractory CLL)

 

[N=85] [24]

   

[N=40] [40]

[N=40] [41]

ORR

71%

71% (CR=10%, PR=61%)

67 % (CR=3%, PR=64%)

50% (PR=50%, CR=0%)

85%

100%

  1. ORR = overall response rate; CR = complete remission; PR = partial remission.